OncoCyte (OCX)
(Delayed Data from NSDQ)
$3.24 USD
+0.07 (2.05%)
Updated Jul 23, 2024 03:59 PM ET
After-Market: $3.22 -0.02 (-0.46%) 6:20 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for OncoCyte Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 1 | 8 | 1 | 0 |
Cost Of Goods | 1 | 1 | 8 | 2 | 0 |
Gross Profit | 0 | 0 | 0 | -1 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 26 | 18 | 74 | 29 | 22 |
Income After Depreciation & Amortization | -25 | -18 | -74 | -30 | -22 |
Non-Operating Income | 0 | -1 | 1 | -1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -25 | -19 | -73 | -31 | -22 |
Income Taxes | 0 | 0 | -9 | -1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -25 | -19 | -64 | -30 | -22 |
Extras & Discontinued Operations | -3 | -54 | 0 | 0 | 0 |
Net Income (GAAP) | -28 | -73 | -64 | -30 | -22 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -23 | 6 | -70 | -27 | -22 |
Depreciation & Amortization (Cash Flow) | 2 | 24 | 4 | 3 | 0 |
Income After Depreciation & Amortization | -25 | -18 | -74 | -30 | -22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 7.65 | 5.54 | 4.45 | 3.27 | 2.57 |
Diluted EPS Before Non-Recurring Items | -4.37 | -3.40 | -7.60 | -9.20 | -8.80 |
Diluted Net EPS (GAAP) | -3.75 | -13.20 | -14.40 | -9.20 | -8.80 |
Fiscal Year end for OncoCyte Corporation falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.18 | 0.31 | 0.43 | 0.46 |
Cost Of Goods | NA | 0.27 | 0.43 | 0.18 | 0.19 |
Gross Profit | NA | -0.10 | -0.12 | 0.25 | 0.27 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 9.17 | 16.07 | 6.77 | 8.57 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -9.27 | -16.19 | -6.52 | -8.30 |
Non-Operating Income | NA | 0.15 | 0.35 | -0.09 | -0.04 |
Interest Expense | NA | 0.02 | 0.16 | -0.12 | 0.00 |
Pretax Income | NA | -9.13 | -15.99 | -6.49 | -8.33 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -9.13 | -15.99 | -6.49 | -8.33 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -9.13 | -15.99 | -6.49 | -8.33 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 8.26 | NA | 8.26 | 8.09 |
Diluted EPS Before Non-Recurring Items | NA | -1.13 | NA | -0.57 | -1.07 |
Diluted Net EPS (GAAP) | NA | -1.13 | -2.27 | -0.81 | -1.07 |